Serum and salivary sialic acid as a biomarker in oral potentially malignant disorders and oral cancer

M. Dadhich, V. Prabhu, V. R. Pai, J. D'Souza, S. Harish, M. Jose

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Aberrant glycosylation is the universal feature of cancer and components of various glycoconjugates, such as sialic acid is found to rise in various malignancies. The objective of this study was to evaluate the serum and salivary sialic acid in oral potentially malignant disorders (OPMD) and oral cancer (OC) to investigate the possibility of using this as a diagnostic marker. Materials and Methods: The study included 85 subjects, who were grouped as control (30), OPMD patients (25), and oral cancer patients (30). Serum and unstimulated whole saliva was collected from subjects of all groups and sialic acid estimation was done using spectrophotometry. The results were tabulated and analyzed statistically. Results: The mean serum sialic acid levels in normal, OPMD, and oral cancer group were 7.515, 19.620, and 55.235 mg/dL, respectively, whereas the levels of salivary sialic acid were 1.5113, 2.3302, and 9.0304 mg/dL, respectively. A very highly significant rise (P < 0.005) in serum and salivary sialic acid was observed in the study subjects compared with that of the control. Conclusions: The present study showed a significant and gradual increase in serum and salivary sialic acid from control to oral potentially malignant disorders to oral cancer. From this study we can suggest that sialic acid can be used as a reliable biomarker. As this monosaccharide is observed in saliva in detectable quantity, saliva can be used as a diagnostic medium for screening and early detection of oral cancer.

Original languageEnglish
Pages (from-to)214-218
Number of pages5
JournalIndian Journal of Cancer
Volume51
Issue number3
DOIs
Publication statusPublished - 01-01-2014

Fingerprint

Mouth Neoplasms
N-Acetylneuraminic Acid
Biomarkers
Serum
Saliva
Glycoconjugates
Monosaccharides
Spectrophotometry
Glycosylation
Early Detection of Cancer
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Dadhich, M. ; Prabhu, V. ; Pai, V. R. ; D'Souza, J. ; Harish, S. ; Jose, M. / Serum and salivary sialic acid as a biomarker in oral potentially malignant disorders and oral cancer. In: Indian Journal of Cancer. 2014 ; Vol. 51, No. 3. pp. 214-218.
@article{6cca7b0cb8ab4784b141b15aab7f4d9d,
title = "Serum and salivary sialic acid as a biomarker in oral potentially malignant disorders and oral cancer",
abstract = "Background: Aberrant glycosylation is the universal feature of cancer and components of various glycoconjugates, such as sialic acid is found to rise in various malignancies. The objective of this study was to evaluate the serum and salivary sialic acid in oral potentially malignant disorders (OPMD) and oral cancer (OC) to investigate the possibility of using this as a diagnostic marker. Materials and Methods: The study included 85 subjects, who were grouped as control (30), OPMD patients (25), and oral cancer patients (30). Serum and unstimulated whole saliva was collected from subjects of all groups and sialic acid estimation was done using spectrophotometry. The results were tabulated and analyzed statistically. Results: The mean serum sialic acid levels in normal, OPMD, and oral cancer group were 7.515, 19.620, and 55.235 mg/dL, respectively, whereas the levels of salivary sialic acid were 1.5113, 2.3302, and 9.0304 mg/dL, respectively. A very highly significant rise (P < 0.005) in serum and salivary sialic acid was observed in the study subjects compared with that of the control. Conclusions: The present study showed a significant and gradual increase in serum and salivary sialic acid from control to oral potentially malignant disorders to oral cancer. From this study we can suggest that sialic acid can be used as a reliable biomarker. As this monosaccharide is observed in saliva in detectable quantity, saliva can be used as a diagnostic medium for screening and early detection of oral cancer.",
author = "M. Dadhich and V. Prabhu and Pai, {V. R.} and J. D'Souza and S. Harish and M. Jose",
year = "2014",
month = "1",
day = "1",
doi = "10.4103/0019-509X.146720",
language = "English",
volume = "51",
pages = "214--218",
journal = "Indian Journal of Cancer",
issn = "0019-509X",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

Serum and salivary sialic acid as a biomarker in oral potentially malignant disorders and oral cancer. / Dadhich, M.; Prabhu, V.; Pai, V. R.; D'Souza, J.; Harish, S.; Jose, M.

In: Indian Journal of Cancer, Vol. 51, No. 3, 01.01.2014, p. 214-218.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum and salivary sialic acid as a biomarker in oral potentially malignant disorders and oral cancer

AU - Dadhich, M.

AU - Prabhu, V.

AU - Pai, V. R.

AU - D'Souza, J.

AU - Harish, S.

AU - Jose, M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Aberrant glycosylation is the universal feature of cancer and components of various glycoconjugates, such as sialic acid is found to rise in various malignancies. The objective of this study was to evaluate the serum and salivary sialic acid in oral potentially malignant disorders (OPMD) and oral cancer (OC) to investigate the possibility of using this as a diagnostic marker. Materials and Methods: The study included 85 subjects, who were grouped as control (30), OPMD patients (25), and oral cancer patients (30). Serum and unstimulated whole saliva was collected from subjects of all groups and sialic acid estimation was done using spectrophotometry. The results were tabulated and analyzed statistically. Results: The mean serum sialic acid levels in normal, OPMD, and oral cancer group were 7.515, 19.620, and 55.235 mg/dL, respectively, whereas the levels of salivary sialic acid were 1.5113, 2.3302, and 9.0304 mg/dL, respectively. A very highly significant rise (P < 0.005) in serum and salivary sialic acid was observed in the study subjects compared with that of the control. Conclusions: The present study showed a significant and gradual increase in serum and salivary sialic acid from control to oral potentially malignant disorders to oral cancer. From this study we can suggest that sialic acid can be used as a reliable biomarker. As this monosaccharide is observed in saliva in detectable quantity, saliva can be used as a diagnostic medium for screening and early detection of oral cancer.

AB - Background: Aberrant glycosylation is the universal feature of cancer and components of various glycoconjugates, such as sialic acid is found to rise in various malignancies. The objective of this study was to evaluate the serum and salivary sialic acid in oral potentially malignant disorders (OPMD) and oral cancer (OC) to investigate the possibility of using this as a diagnostic marker. Materials and Methods: The study included 85 subjects, who were grouped as control (30), OPMD patients (25), and oral cancer patients (30). Serum and unstimulated whole saliva was collected from subjects of all groups and sialic acid estimation was done using spectrophotometry. The results were tabulated and analyzed statistically. Results: The mean serum sialic acid levels in normal, OPMD, and oral cancer group were 7.515, 19.620, and 55.235 mg/dL, respectively, whereas the levels of salivary sialic acid were 1.5113, 2.3302, and 9.0304 mg/dL, respectively. A very highly significant rise (P < 0.005) in serum and salivary sialic acid was observed in the study subjects compared with that of the control. Conclusions: The present study showed a significant and gradual increase in serum and salivary sialic acid from control to oral potentially malignant disorders to oral cancer. From this study we can suggest that sialic acid can be used as a reliable biomarker. As this monosaccharide is observed in saliva in detectable quantity, saliva can be used as a diagnostic medium for screening and early detection of oral cancer.

UR - http://www.scopus.com/inward/record.url?scp=84920102784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920102784&partnerID=8YFLogxK

U2 - 10.4103/0019-509X.146720

DO - 10.4103/0019-509X.146720

M3 - Article

VL - 51

SP - 214

EP - 218

JO - Indian Journal of Cancer

JF - Indian Journal of Cancer

SN - 0019-509X

IS - 3

ER -